Advertisement

Picture [iito] Life Science Business Portals Media Data 2022 650x100px
Document › Details

IMIdomics, Inc.. (2/15/22). "Press Release: IMIDomics, Inc. Announces Strategic Investment from Drug Discovery and Research Leader Evotec SE". San Rafael, CA & Barcelona.

Organisations Organisation IMIDomics Inc.
  Group IMIDomics (Group)
  Organisation 2 Evotec SE (FSE: EVT, MDA X/TecDAX, Nasdaq: EVO)
  Group Evotec (Group)
Products Product drug discovery
  Product 2 anti-inflammatory drug
Index term Index term IMIDomics–Evotec: investment, 202202 strategic equity investment €na by Evotec
Persons Person Lanthaler, Werner (Evotec AG 200903– CEO before Intercell AG CFO before Austrian Industrial Assoc before McKinsey)
  Person 2 Harrison, Juan (IMIDomics 202107 CEO)
     


IMIDomics, Inc., a privately held global biotechnology company focused on the discovery and development of new targets and medicines for the treatment of patients with immune-mediated inflammatory diseases (IMIDs), announced today that Evotec SE (FSE: EVT; MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) has made an equity investment in the company. In conjunction with the investment, an Evotec representative will join the IMIDomics board of directors. No financial details were disclosed.

IMIDs affect nearly 1 in 10 people – limiting quality of life and creating significant challenges to physical and mental well-being. The complexity of these diseases means even getting a diagnosis can be a long-term struggle for patients, and then finding a treatment that works can be a frustrating, time-consuming trial and error process.

This new investment will further advance IMIDomics’ Precision Discovery™ Engine which enables a deep understanding of how IMIDs work within patients via a combination of clinical and computational expertise with patient biological samples from the Vall d’Hebron Hospital IMID Biobank, exclusive access to curated, secure and anonymized clinical data collected from more than 17,000 IMID patients and control subjects from across 150 health centers, and proprietary biomolecular signatures generated by IMIDomics from these same patients. Ultimately, the Engine’s purpose is to discover medicines that will materially impact IMID patients’ lives.

“Evotec and IMIDomics are perfectly aligned on their goal to leverage data to discover and develop precise-acting, effective medicines of the future,” said Dr. Werner Lanthaler, CEO of Evotec. “By joining IMIDomics as a minority shareholder, we are excited to further grow our EVOequity portfolio of highly promising companies with complementary technologies and assets.”

“The still unmet needs in this immense and ever-expanding category of illnesses demand that we leverage patient data holistically to decipher the causes of disease and find treatments. Evotec’s dedication to the use of data in drug discovery is why they are such a strong fit with IMIDomics – they share our core mission of applying intersectional data to uncover the next generation of targeted medicines and companion diagnostic tools needed to more precisely address complex IMID diseases and positively impact the experience and outcomes for people living with them,” said Juan Harrison, CEO of IMIDomics.


IMIDomics was founded in Barcelona, Spain in 2015 by Dr. Sara Marsal, Head of the Rheumatology Department at the Vall d’Hebron University Hospital, and Dr. Richard M. Myers, President and Scientific Director at the HudsonAlpha Institute for Biotechnology. Existing investors in IMIDomics include DNS Capital, Tao Capital, The Pritzker Organization and Bristol Myers Squibb.

To learn more about IMIDomics, please visit www.imidomics.com.


Contacts

IMIDomics Press Contact:
Sylvia Aranda at Real Chemistry
saranda@realchemistry.com

   
Record changed: 2022-03-17

Advertisement

Picture [iito] No Tracking 650x100px

More documents for IMIDomics (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

Picture ConsulTech GmbH Berlin Grant Application and Coordination 650x80px




» top